Evidence map›Paper›PMID 15471179›Full record

Trial reportWiener klinische Wochenschrift2004

Creutzfeldt-Jakob disease in Slovenia from 1985 to 2003.

Mara Popović, Damjan Glavac, Sava Smerkolj, Viktor Svigelj, Gregor Kalan, Vesna Galvani, Maja Cernilec, Maja Bresjanac

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Wiener klinische Wochenschrift, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mara PopovićInstitute of Pathology, Medical Faculty, University of Ljubljana, Slovenia. mara.popovic@mf.uni-lj.si
Damjan Glavac
Sava Smerkolj
Viktor Svigelj
Gregor Kalan
Vesna Galvani
Maja Cernilec
Maja Bresjanac

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe epidemic of bovine spongiform encephalopathy and subsequent emergence of a new variant of Creutzfeldt-Jakob disease have raised great public concern, initiating improved and prospective surveillance of human prion diseases in Europe and all over the world. This report briefly presents the epidemiology, clinical data, neuropathology, immunohistochemistry, biochemistry, and prion-protein gene analysis of Slovenian cases of Creutzfeldt-Jakob disease from January 1985 to the end of 2003. MATERIALS, METHODS AND

resultsDuring the 19-year period, 39 suspected cases of Creutzfeldt-Jakob disease were referred and 22 were confirmed. The prion-protein gene was analyzed in 12 of the confirmed cases and the protein glycosylation pattern in 11. There was a low average incidence of Creutzfeldt-Jakob disease (0.5/million) throughout the surveillance period, but a pronounced increase between January 2001 and December 2003 (to 1.9/million/year). A high female to male ratio (2.5/1) was noted. All of the confirmed cases were defined as sporadic Creutzfeldt-Jakob disease based on the clinical data, neuropathological findings, glycosylation pattern, and gene analysis. All tested cases had a type-2 glycosylation pattern; eleven of the twelve tested patients were homozygous at codon 129 of the prion-protein gene (1 VV and 10 MM) and one was heterozygous.

conclusionThe small number of Slovenian cases of sporadic Creutzfeldt-Jakob disease during the last 19 years has shown a pronounced increase in incidence, reflecting improved surveillance, and a high female to male ratio, where female cases are more than twice as numerous as male cases.

Indexed as

AgedAge DistributionCreutzfeldt-Jakob SyndromeFemaleGenetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedPrevalencePrPSc ProteinsRisk AssessmentRisk FactorsSex DistributionSloveniaSurvival AnalysisPrPSc Proteins

Identifiers

PMID15471179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.